产品说明书

ATN-161

Print
Chemical Structure| 262438-43-7 同义名 : -
CAS号 : 262438-43-7
货号 : A370715
分子式 : C23H35N9O8S
纯度 : 98%
分子量 : 597.644
MDL号 : MFCD30478885
存储条件：

粉末 Keep in dark place,Inert atmosphere,Store in freezer, under -20°C

液体 -20°C:3-6个月-80°C:12个月
溶解度 : -
动物实验配方：
生物活性
靶点

  • Integrin
描述 The combination of ATN-161 and 5-FU results in a notable reduction in tumor cell proliferation compared to both control and monotherapy (p<0.01). Furthermore, the combined treatment leads to a significant increase in apoptotic (TUNEL-positive) tumor cells (p<0.03), whereas monotherapy does not increase the number of TUNEL-positive tumor cells. Following a 48-hour incubation period, ATN-161 treatment leads to a significant decrease in endothelial cell (EC) count (21% reduction) compared to control (p<0.03) [1]. ATN-161 inhibits VEGF-induced migration and capillary tube formation in hCECs, while showing no effect on proliferation. It reduces the number of cells migrating in response to VEGF in a dose-dependent manner, starting at 100 nM (P<0.001 vs. VEGF group)[2].
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

1.67mL

0.33mL

0.17mL

8.37mL

1.67mL

0.84mL

16.73mL

3.35mL

1.67mL
参考文献

[1]Stoeltzing O, et al. Inhibition of integrin alpha5beta1 function with a small peptide (ATN-161) plus continuous 5-FU infusion reduces colorectal liver metastases and improves survival in mice. Int J Cancer. 2003 Apr 20;104(4):496-503.

[2]Wang W, et al. The antiangiogenic effects of integrin alpha5beta1 inhibitor (ATN-161) in vitro and in vivo. Invest Ophthalmol Vis Sci. 2011 Sep 14;52(10):7213-20.